The primary objective of this study is to determine the long-term safety and tolerability of
ataluren in participants with nonsense mutation cystic fibrosis (nmCF) who completed
participation in the double-blind study PTC124-GD-009-CF (NCT00803205), as assessed by
adverse events and laboratory abnormalities. The secondary objective of this study includes
the assessment of the efficacy of ataluren, as measured by forced expiratory volume in 1
second (FEV1) and pulmonary exacerbation rate, and other safety parameters (for example,
12-lead electrocardiogram [ECG] measurements, vital signs).